Cidofovir ILIs were prepared by diluting a vial of cidofovir 375 mg in 60 ml of 0.9% sodium chloride, obtaining a final concentration of 6.25 mg/ml. Of these 60 ml, 5 syringes of 12 ml were loaded (75 mg of cidofovir in each one), which have a stability of 5 months refrigerated (2-8°C), according previous studies.Intralesional cidofovir treatment started in February 2022. After three drug administrations, a significant improvement in lesions was described by a reduction in both their volume and extension. A bad odor of superficial exudate was also reported, which was solved with first polymyxin and later fusidic acid, both administered topically, twice a day. The patient presented good tolerance to injections, only requiring local anesthesia with lidocaine for pain. Conclusion and RelevanceThis is the first case of use of this formulation of cidofovir ILIs in a patient with anogenital condylomatosis and immune deficiency. Previously, it was used in other manifestations of HPV infection. The formulation also proved to be stable, well-tolerated, and easy to prepare. Therefore, this therapy may be considered a reasonable option for the treatment of HVP condylomatosis when other treatments seem ineffective.

biological therapy with monoclonal antibodies against selective targets may be a suitable option. Aim and Objectives To assess the effectiveness and safety in routine clinical practice of omalizumab, mepolizumab and benralizumab in patients with severe uncontrolled asthma. Material and Methods Retrospective observational study in a regional hospital undergoing patients diagnosed with severe asthma treated with omalizumab, mepolizumab and benralizumab. Effectiveness was assessed based on oral corticosteroid dose reduction, exacerbations and improvement in lung capacity. Safety was demonstrated based on adverse effects onset. Data was obtained from clinical history program and drug dispensing program. Results 30 patients (53% women) with a median age of 56 years (range: 16-78) have received biological drugs in our hospital to treat severe uncontrolled asthma. 9 patients were treated only with omalizumab, 5 with Mepolizumab, 2 with benralizumab; 7 patients sequentially omalizumab!mepolizumab, 5 cases omalizumab!benralizumab and 2 with the three drugs sequentially.52% of patients on omalizumab, 71% of patients on mepolizumab, and 78% on benralizumab experienced a decrease in oral corticosteroid dose. Regarding exacerbations: 65% omalizumab, 85% mepolizumab and 78% benralizumab reduced the number of exacerbations. Improvement in lung capacity as a function of Forced Expiratory Volume in 1 second (FEV1) was observed in 74% of patients on omalizumab, 79% on mepolizumab, and 89% on benralizumab. Adverse reactions occurred in 5 cases treated with omalizumab: arthralgia (2), headache, tiredness, cough; 2 cases with benralizumab: skin rash, nasal congestion; and one case of hypertension with the administration of mepolizumab. Conclusion and RelevanceTreatment with omalizumab, mepolizumab and benralizumab in severe asthma is effective in most patients under normal clinical practice conditions. The frequency of adverse effects is low, being mild in most cases, so they can be considered safe drugs.

Background and Importance The opening of a pharmaceutical care service for onco-haematology patients (OHP) in the midst of the health care crisis caused by the COVID19 pandemic, made it possible to maintain the healthcare activity, avoid the collapse and provide the opportunity to implement Comprehensive Medication Management (CMM). Aim and Objectives To investigate the pharmacotherapeutic experience of OHP in outpatient therapy with CMM services; to know important aspects perceived for the identification of barriers/facilitators that determine the quality of the service and proposals for improvement. Material and Methods Descriptive observational design with a qualitative approach, using informal and semi-structured indepth interviews (participant observation and peer review) during January-June 2021. ATLAS.ti software was used for content analysis. Oncohaematology patients in outpatient therapy with any medication-related problem and who received CMM services were interviewed. Those who, due to cognitive limitation, could not be interviewed or who did not have a caregiver/family member available were excluded. Results 19 interviews were conducted: 57.89% patients and 42.10% caregivers; 57.89% were women. All patients were very satisfied with the care received, the vast majority preferred to be attended by a pharmacist, and valued telepharmacy as an alternative or complementary option. The vision of the pharmacy professional as an expert in medicines improves. They suggest improvement related to location, waiting times and greater accessibility of the pharmacist. After the researchers' reflective process, were identified as barriers: care pressure, limited time/resources, lack of interlevel coordination, and facilitators: prioritisation of interventions, integration of pharmacist in the multidisciplinary team, trust in the pharmacist and the new model of care. Improvement strategies: provision of human/material resources with release of pharmacist's time to provide the CMM, extension of hours, information management with the development of personal learning environment and use of programs for recording/integration of information and interventions. Conclusion and RelevanceDelving into patients' experiences can be key to improving the quality of care. In our case, the implementation of the CMM service in OHP has been a challenge and an opportunity in the current context of the COVID-19 pandemic. The pharmacy adapted to the needs and implemented a new model of care with excellent acceptance by users.

Background Vancomycin is an antibiotic against Gram positive bacteria. Vancomycin is useful in treating infections caused by foreign materials, such as catheters used in haemodialysis. It is eliminated mainly through the renal system, so any renal system alteration affects the concentration of vancomycin. Purpose To assess the effectiveness of vancomycin monitoring in patients undergoing haemodialysis and the effectiveness of the interventions made by the pharmacy service to reach the target concentration. Materials and methods Patients undergoing haemodialysis whose vancomycin levels had been monitored by the pharmacy service between May 2012 to April 2013 at a tertiary level hospital. The variables collected were: age, sex, weight, residual renal function, type of infection, type of microorganism, target level, type of dialysis membrane, initial dose, recommended dose, trough levels and effectiveness of treatment. The target serum concentration was between 15–20 µg/ml in serious infections, and 10–15 µg/ml in milder cases. Results 26 patients undergoing haemodialysis were selected but just 24 were included. 15 men and 9 women, with an average age of 62.5 years and weight between 50 and 119 kg. Of all patients, just 10 had residual renal function. 6 patients used a low flow membrane, 8 patients used an intermediate membrane, 6 patients used a high flow membrane and no data were available from 3 patients. The initial dose varied between 5 mg/kg and 23.8 mg/kg. Recommended doses varied between 0.5–2 g. The target was never reached in 4 patients. The goal was achieved after the initial dose in 4 cases, after <2 recommendations in 2 cases and after <5 recommendations in 6 cases. Conclusions The infection was eradicated in 86% of cases, and the target concentration was reached in 79% of them. These results justify a broader analysis to establish a treatment guide for vancomycin in patients undergoing haemodialysis. No conflict of interest.

Background and importance Digital health is the concept that incorporates information and communication technologies into healthcare services. Nowadays, and favoured by the SARS-CoV-2 pandemic, hospital pharmacy has been forced to adopt digital technologies and tools to improve patient care. Aim and objectives If any area of hospital pharmacy has gained prominence in recent years, it is the area of digital health. Therefore, it was decided to analyse current clinical trials in relation to technological devices or wearables. Material and methods Descriptive study of current clinical trials on technological devices from the pharmacological aspect. The following filters were applied: active trials, devices in digital pharmacy, all phases, all ages and both sexes. The type of device was analysed as intervention, pathology, location, and study topic. Both observational and interventional studies were included. The tool used for evaluation was the ClinicalTrials. gov clinical trials registry. Results Nineteen current active phase clinical trials were analysed. The phases of the projects were: phase I-7, phase II-3, phase III-2 and phase IV-7. The main pathologies of the clinical trials were: musculoskeletal disorders ( 6), chronic obstructive pulmonary disease (3), Parkinson's neurodegenerative diseases (3), oncology (2), autism (1), renal system (1), cardiac system (1) and self-injection devices (1). The main countries conducting clinical trials were: United States (13), Europe (4), Asia (1) and Oceania (1). Seven projects were detected in the patient recruitment phase. Conclusion and relevanceAlthough the use of wearables in the field of hospital pharmacy is a little known topic, it is increasingly gaining prominence in the literature and in scientific research. Digital health is the driver of change towards new models of care between patients and healthcare professionals. Therefore, it is necessary to continue with research and clinical trials to promote digitisation in hospital pharmacy.